Abstract: Iparomlimab and Tuvonralimab (QL1706) is the first bifunctional antibody combination in the world to simultaneously target programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). By concurrently blocking the PD-1/PD-L1 and CTLA-4/B7 signaling pathways, it is able to enhance anti-tumor immune activation and help maintain a more durable immune response. On September 26, 2024, QL1706 received its first approval in China for the treatment of recurrent or metastatic cervical cancer after failure of platinum-based chemotherapy. In addition to cervical cancer, clinical studies have also shown encouraging anti-tumor activity in several other solid tumors, including lung cancer, nasopharyngeal carcinoma, and hepatocellular carcinoma. In terms of safety, most treatment-emergent adverse events (TEAEs) reported with QL1706 have been mild to moderate, while the incidence of high-grade immune-related adverse events (irAEs) has remained relatively low. This review summarizes the molecular design, mechanisms of action, and key clinical advances of QL1706, with the aim of providing a reference for its more rational use in clinical practice.